Serum Levels of MicroRNA-371a-3p (M371) Can Predict Absence or Presence of Vital Disease in Residual Masses After Chemotherapy of Metastatic Seminoma.

Autor:	Dieckmann KP; Department of Urology, Asklepios Klinik Altona, Hamburg, Germany.; Department of Urology, Albertinen Krankenhaus, Hamburg, Germany., Klemke M; Faculty of Biology & Chemistry, University of Bremen, Bremen, Germany., Grobelny F; Faculty of Biology & Chemistry, University of Bremen, Bremen, Germany., Radtke A; mirdetect GmbH, Bremerhaven, Germany., Dralle-Filiz I; Department of Urology, Albertinen Krankenhaus, Hamburg, Germany., Wülfing C; Department of Urology, Asklepios Klinik Altona, Hamburg, Germany., Belge G; Faculty of Biology & Chemistry, University of Bremen, Bremen, Germany.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2022 May 06; Vol. 12, pp. 889624. Date of Electronic Publication: 2022 May 06 (Print Publication: 2022).
DOI:	10.3389/fonc.2022.889624
Abstrakt:	Background: Radiological evaluation of postchemotherapy residual masses of metastatic seminoma is characterized by poor diagnostic accuracy. Serum levels of microRNA-371a-3p (M371) involve high specificity and sensitivity for the primary diagnosis of seminoma. We evaluated if M371 levels can indicate the presence of vital disease in postchemotherapy residual masses in patients with metastatic seminoma. Methods: Twenty-three seminoma patients (median age 52 years) with residual masses had posttreatment measurements of serum M371 levels (group A), fourteen of whom had measurements also beforehand. The posttreatment results were compared with the clinical outcome during follow-up. Eleven patients with complete remission after treatment of metastatic seminoma (group B) and 33 men with non-malignant testicular diseases (group C) served as controls. M371 serum levels were measured by quantitative real-time PCR using miR-30b-5p as endogenous control. An evaluation was performed with descriptive statistical methods. Results: Twenty-two patients of Group A had uneventful follow-up so far, twenty-one of whom had M371 level <5, and one other had a mildly elevated level below relative quantity (RQ) = 10. One patient with a level of RQ = 26.2 rapidly progressed. The median posttreatment M371 level of the non-progressing patients of group A is not significantly different from the median level of the control group with complete remission (B). Before treatment, the median M371 levels in groups A and B were 507.6 and 143.9, respectively. In both groups, significant drops in M371 levels resulted from treatment. Conclusion: Normal M371 serum levels at the time of completion of treatment of metastatic seminoma indicate the absence of vital seminoma in residual masses, while elevated levels >RQ = 10 predict the presence of disease. The optimal timing of M371 measurement after chemotherapy and the appropriate cutoff level still need to be determined. Based on the present results, measuring serum M371 levels involves the potential of a novel tool for assessing postchemotherapy residual masses of metastatic seminoma. Competing Interests: K-PD and GB declare ownership shares of each 9.71% of mirdetect GmbH, Bremerhaven, Germany. AR is an employee of mirdetect, GmbH, Bremerhaven, Germany. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Dieckmann, Klemke, Grobelny, Radtke, Dralle-Filiz, Wülfing and Belge.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu